All About Acute Lymphoblastic Leukaemia | RISE Research

This paper is a review of acute lymphoblastic leukaemia (ALL), bringing together the disease's biology, diagnosis and the spectrum of current and emerging treatments. ALL is a cancer of the blood and bone marrow marked by the overproduction of immature lymphoblasts, and the paper sets out to explain its mechanisms and the therapeutic landscape in an accessible, structured way. The review surveys the major treatment modalities and how they fit together across the course of the disease, including conventional chemotherapy as the long-standing backbone of treatment, and newer approaches such as immunotherapy, CAR-T cell therapy and gene therapy. A particular concern is the problem of leukaemia relapse, where disease returns after initial treatment, and how emerging precision-medicine strategies aim to target the disease more specifically and improve outcomes for patients who do not respond to, or relapse after, standard regimens. By placing established and cutting-edge therapies side by side, the paper's focus is to clarify the trajectory of ALL treatment, from broad cytotoxic chemotherapy toward more targeted, personalised interventions that harness the immune system or correct underlying genetic drivers. Grounded in medicine and biology, it synthesises how each approach works, what advantages newer therapies such as CAR-T and gene therapy offer, and where challenges remain, particularly relapse and the need for precision approaches. The result is an overview intended to make a complex and clinically important cancer comprehensible, mapping the move toward precision medicine in the management of acute lymphoblastic leukaemia and the promise these advances hold for improving survival.